Evidence map›Paper›PMID 42274815›Full record

ArticleNeurosurgical review2026

MIB-1 index predicts low recurrence risk after subtotal resection of meningiomas: a retrospective study of 505 patients.

Joonas Laajava, Jenni Määttä, Miikka Korja

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Joonas LaajavaDepartment of Neurosurgery, University of Helsinki and Helsinki University Hospital, P.O. Box 266, Helsinki, FI-00029, Finland. joonas.laajava@helsinki.fi.ORCID http://orcid.org/0009-0003-1078-4718
Jenni MäättäDepartment of Neurosurgery, University of Helsinki and Helsinki University Hospital, P.O. Box 266, Helsinki, FI-00029, Finland.ORCID http://orcid.org/0009-0007-8786-3827
Miikka KorjaDepartment of Neurosurgery, University of Helsinki and Helsinki University Hospital, P.O. Box 266, Helsinki, FI-00029, Finland.ORCID http://orcid.org/0000-0002-4463-6954

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Ki-67/MIB-1 index, a biomarker of cellular proliferation, holds prognostic value. In meningiomas, MIB-1 correlates with recurrence, with a proposed 4.1% cutoff. This study aimed to identify optimal patient groups for the MIB-1 proliferation index threshold, hypothesizing improved recurrence prediction within stratified subgroups. We performed a retrospective cohort study of adult patients (≥ 18 years) undergoing primary meningioma resection (2005-2018) with available MIB-1 proliferation index and at least five years of MRI follow-up. Meningiomas of all WHO grades were included. Of 505 patients (median age 59 years) meeting inclusion criteria, 340 (67.3%) were female, with meningiomas predominantly WHO grade I (55.8%) or II (41.6%). subtotally resected (STR) WHO grade I meningiomas account for a total of 58 (20.6%) cases out of all 282 (GTR + STR) surgically treated grade I meningiomas. Of these 58 STR grade I meningiomas, 21 (36%) recurred within the 5-year follow-up period. Among 35 subtotally resected grade I meningiomas with MIB-1 values of ≤ 4%, only four (11%) recurred in five years. In the multivariable analysis, preoperative meningioma volume ((p = 0.02, HR 1.02) per 1 cm

Indexed as

Ki-67 AntigenMeningeal NeoplasmsMeningiomaNeoplasm Recurrence, LocalAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeurosurgical ProceduresPrognosisRetrospective StudiesBiomarkers, TumorKi-67 AntigenMeningiomaMIB-1 labeling indexNeural crestRecurrenceReoperationResection

Identifiers

PMID42274815
PMCPMC13260087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.